



CIS Pharmaceutical Marketing Authorisation Strategy Course

31 January – 4 February 2027
Zanzibar

CIS Pharmaceutical Marketing Authorisation Strategy Course

Ref: 1458_207629 **Date:** 31 January – 4 February 2027 **Location:** Zanzibar **Fees:** 5500 Euro

Overview

CIS Pharmaceutical Marketing Authorisation Strategy Course is a one-week advanced programme for pharmaceutical and biotechnology regulatory affairs professionals, submission managers, quality teams, market-access coordinators, legal and compliance professionals, and project leaders working with CIS markets. Participants build a CIS Authorisation Strategy Portfolio connecting jurisdiction and route mapping, EAEU medicinal product registration, national pathways, dossier evidence, language controls, submission readiness, authority interactions, response governance, lifecycle changes, regulatory intelligence, and cross-functional decisions. Agile Leaders Training Center treats the region as multiple legal and procedural environments, requiring current local verification and authorized advice; the course provides process education and no legal opinion, approval guarantee, or substitute for an authority's current rules.

Who Should Attend

- Pharmaceutical and biotechnology regulatory affairs professionals
- Submission, dossier, and lifecycle managers
- Quality, clinical, nonclinical, and pharmacovigilance contributors
- Market-access, legal, compliance, and localization coordinators
- Project leaders governing CIS and EAEU regulatory programmes

The course assumes experience in regulatory affairs, product development, quality, submissions, compliance, or market entry. Participants must verify current requirements, interpretations, fees, timelines, forms, representation rules, and language obligations with the responsible authority and qualified local advisers before acting.

Departments and Industries

The course supports organizations planning pharmaceutical or biotechnology authorization work across CIS jurisdictions and the EAEU common market.

- Pharmaceutical and biotechnology companies
- Regulatory affairs and product-registration functions
- Quality, clinical, nonclinical, and pharmacovigilance teams
- Legal, compliance, localization, and market-access functions
- Contract research, consulting, and dossier-support organizations

Learning Objectives

By the end of this course, participants will be able to:

- Distinguish CIS geographic scope, EAEU common procedures, and national authorization routes
- Build a current-source jurisdiction and procedure map
- Classify product, applicant, route, reference state, and target-market decisions
- Structure a CIS pharmaceutical dossier course evidence and gap matrix
- Plan language, translation, legalization, product-information, and labeling controls
- Conduct submission-readiness, question-response, and authority-interaction governance
- Plan pharmaceutical variations and renewals with lifecycle calendars
- Maintain CIS regulatory intelligence, risk, decision, and accountability registers

Course Agenda

Day 1: Jurisdiction, Authority, and Route Strategy

- CIS Market and Jurisdiction Scope Map
- EAEU and National Procedure Boundary
- Responsible Authority and Current-Source Register
- Product, Applicant, and Route Classification
- Reference-State and Target-Market Decision Record

Day 2: Dossier and Evidence Strategy

- Dossier Structure and Content Map
- Quality, Nonclinical, Clinical, and Safety Evidence Matrix
- Biological and High-Technology Product Considerations
- Gap, Dependency, Owner, and Due-Date Register
- Inspection and Quality-System Readiness Dependencies

Day 3: Language, Product Information, and Submission Readiness

- Language, Translation, Certification, and Legalization Plan
- Product Information, Patient Leaflet, Labeling, and Packaging Control
- Electronic Application and Administrative Document Checklist
- Submission Readiness and Technical Validation Review
- Version, Document, and Evidence Traceability

Day 4: Review, Questions, and Authority Interaction

- Examination and Review Milestone Map
- Authority Question Intake and Triage
- Response Evidence, Review, Approval, and Submission Workflow
- Commitment, Inspection, Deficiency, and Escalation Log
- Agency Interaction and Decision Record

Day 5: Lifecycle Governance and Regulatory Intelligence

- Variation, Re-registration, Renewal, and Maintenance Calendar
- Post-Authorization Information and Labeling Change Control
- CIS Regulatory Intelligence Course Monitoring Register
- Cross-Functional Risk and Governance Review
- Capstone: CIS Authorisation Strategy Portfolio

Practical Exercises

The course uses fictional regulatory scenarios and requires participants to verify every live requirement through current authoritative sources.

- Suggested activity: classify a product and map EAEU and national procedure options.
- Suggested activity: build a dossier evidence, language, and readiness matrix.
- Suggested activity: govern an authority question from intake through approved response.
- Suggested activity: create a lifecycle calendar and regulatory-intelligence decision brief.

FAQs

Who should attend a CIS pharmaceutical marketing authorisation course?

It suits experienced regulatory affairs, submission, quality, clinical, safety, legal, compliance, localization, market-access, and project professionals working with pharmaceuticals or biotechnology products.

Is there one marketing-authorisation route for all CIS markets?

No. The course begins with jurisdiction and route mapping. Teams distinguish EAEU common procedures from national routes and verify current scope, authority, forms, evidence, languages, representation, and lifecycle requirements for each intended market.

What does EAEU medicinal product registration involve?

The course examines process planning for registration and examination, dossier structure, reference and target-market choices, mutual-recognition concepts, product information, authority questions, and lifecycle procedures. It does not interpret law for a live application.



Does the course cover biotechnology products?

Yes, at the strategy and governance level. Participants identify additional product classification, evidence, quality, inspection, and dossier dependencies and refer detailed scientific and legal decisions to authorized specialists.

What practical outputs will participants complete?

Outputs include a jurisdiction map, source register, route record, dossier matrix, language plan, readiness checklist, response workflow, interaction log, lifecycle calendar, intelligence register, risk review, and strategy portfolio.